CMS Trims Down List of Drugs Targeted for Price Hike Penalties

The US Centers for Medicare and Medicaid Services (CMS) has pulled 7 drugs from its list of medicines facing penalties for drug price hikes. The Inflation Reduction Act included a provision that would penalize drug manufacturers for raising the price of drugs faster than inflation. This brings the total down to 20 drugs.

According to Christopher Newman, “Pfizer remains the drugmaker with the most on the list at five, although they are older, lower revenue products. The list also includes AbbVie’s top-selling inflammatory disease drug Humira and Seagen’s bladder cancer drug Padcev.”

To read more, click here.

(Source: Biopharma Dive, March 31^st, 2023)